Analysts Raise Price Targets For BridgeBio Pharma

BridgeBio Pharma (NASDAQ:BBIO) received updated analyst coverage in late January and early February 2026, with Barclays initiating an Overweight rating at a $157 price target on Jan. 27 and Bank of America raising its target to $88 on Feb. 3 (from $85) while maintaining a Buy. Analysts cited biotech sector tailwinds and expected M&A, though pre-announcements may mute the company’s upcoming Q4 market impact.